menu
ALLOTCBB Top Rated Top Upgraded Most Active Gainers Losers

ARCH BIOPARTNERS I (ACHFF)
0.3468 0 (0%)  11-10 15:55
Open: 0 Prev Close: 0.3468
High: 0 Low: 0
Volume: 0 Market Cap: 18.42M
Year High: 0 Year Low: 0
Stock Technical Analysis
Overall       
Targets Six months: 0.4061    One year: 0.4333
Supports Support1: 0.3100   Support2: 0.2579
Resistances Resistance1: 0.3477    Resistance2: 0.3710 
Pivot Point 0.3364 
Moving Averages MA(5): 0.3238      MA(20):  

MA(100):   0     MA(250):  
MACD MACD(12,26): -10000000000.000  -10000000000    Signal(12,26,9): -10000000000.000  -10000000000
Stochastic Oscillator %K(14,3): 18.172      %D(3): -10000000000.000  -10000000000
RSI RSI(14): 35.043 
52-Week High: 0.3710  Low: 0.3100  Change(%): -12
Average Volume(K) 3-Month: -10000000000  10-Days: 4
Moving Averages analysis
Price and moving averages has closed below its Short term moving average. Short term moving average is below its mid-term; and below long term moving averages. From the relationship between price and moving averages; we can see that: this stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
Bollinger Bands Analysis
Bollinger Bands has closed above bottom band by 17.6%; Bollinger Bands are 0% narrower than normal.

Stoxline

Stock Chart

Top 100 stocks

Stock News
Arch Biopartners Inc. Opens the Market
Mon, 30 Mar 2015 15:36:02 GMT

Arch Biopartners Appoints Patrick Vink to Board of Directors
Mon, 12 Dec 2016 12:45:00 GMT

Arch Biopartners Announces Non-Brokered Private Placement Financing
Tue, 21 Feb 2017 13:30:00 GMT

Arch Biopartners Appoints Adrian Haigh to Board of Directors
Thu, 21 Aug 2014 12:22:30 GMT

Arch Biopartners Engages Nucro Technics to Begin Toxicology Studies for Metablok
Wed, 01 Nov 2017 14:03:45 GMT

Arch Biopartners Closes Convertible Note Financing
Tue, 24 Oct 2017 12:00:00 GMT

0.3468
Sun, 02 Apr 2017 14:52:02 GMT

Drug for Pulmonary Infections in Cystic Fibrosis Is Focus of Collaboration ...
Tue, 05 Apr 2016 15:40:58 GMT

Arch Biopartners Inc (ACH) Is Yet to See Trading Action on Nov 16
Thu, 16 Nov 2017 19:07:30 GMT

Arch Nears First Clinical Trial of AB569 as Treatment for Antibiotic-Resistant ...
Tue, 18 Apr 2017 12:00:00 GMT